Table 1.
Growth inhibition of K8, E-K8, or Z-K8 against human tumor cell lines.
| Cell line | Origin | IC50 (μM) |
||
|---|---|---|---|---|
| K8 | E-K8 | Z-K8 | ||
| AGS | Gastric carcinoma | ND | ND | 2.5 |
| J5 | Hepatocarcinoma | 21.5 | ND | 2.5 |
| LNCaP | Androgen-dependent, prostate adenocarcinoma |
4.3 | >20 | 1 |
| PC3 | Androgen-independent, prostate adenocarcinoma | >20 | >20 | 4.5 |
| A549 | Lung adenocarcinoma | 18.5 | >20 | 5 |
| H460 | Lung adenocarcinoma | 20.0 | >20 | 10.0 |
| H1299 | Lung adenocarcinoma | 20.5 | >20 | 12.5 |
| A549-T12 | Lung adenocarcinoma | 10.0 | >20 | 4.5 |
| OEC-M1 | Oral squamous cell carcinoma | ND | >1 | 1 |
IC50: drug concentration that inhibits cell division by 50% after 48 h.
ND: not determined, or concentration >100 μM.